You are here

Article Text

Article menu

Download PDFPDF

Ovarian Cancer
Impact of Routine Follow-Up Examinations on Life Expectancy in Ovarian Cancer Patients: A Simulation Study
  1. Sandra M. E. Geurts, MSc*,
  2. Femmie de Vegt, PhD*,
  3. Anne M. van Altena, MD†,
  4. Vivianne C. G. Tjan-Heijnen, MD, PhD‡,
  5. Leon F. A. G. Massuger, MD, PhD†,
  6. Eddy M. Adang, PhD*,
  7. Jos A. A. M. van Dijck, PhD* and
  8. André L. M. Verbeek, MD, PhD*
  1. *Departments of Epidemiology, Biostatistics and HTA,
  2. †Departments of Obstetrics and Gynecology, Radboud University Nijmegen Medical Centre, Nijmegen; and
  3. ‡Division of Medical Oncology, GROW–School for Oncology and Developmental Biology, Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands.
  1. Address correspondence and reprint requests to Sandra M. E. Geurts, MSc, Department of Epidemiology, Biostatistics and HTA, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500HB Nijmegen, the Netherlands. E-mail: S.Geurts{at}ebh.umcn.nl.

Abstract

Objective The clinical benefit of routine follow-up in patients treated for ovarian cancer is subject to debate. In this study, the magnitude of the potential survival benefit of routine examinations was evaluated by Markov modeling.

Methods The clinical course of ovarian cancer was simulated using a 4-state nonstationary Markov model. Risk of recurrence and mortality probabilities were derived from individual patient data and Statistics Netherlands. The life expectancy was simulated for 3 follow-up scenarios: a current, withholding (all recurrences detected symptomatically), and perfect follow-up program (all recurrences detected asymptomatically). The impact of effective recurrence treatment in the future was modeled by varying the mortality ratio between patients with asymptomatically versus symptomatically detected recurrences. The model was validated using empirical data.

Results The mean life expectancy of patients, aged 58 years and in complete clinical remission after primary treatment, was 10.8 years. Varying the transition probabilities with ±25% changed the life expectancy by up to 1.1 years. The modeled life expectancy for the withholding and perfect follow-up scenarios was also 10.8 years and insensitive to model assumptions. In patients with stages IIB to IV, the life expectancy was 7.0 years, irrespective of follow-up strategy. A mortality ratio of 0.8 for patients with asymptomatically versus symptomatically detected recurrences resulted in a gain in life expectancy of 5 months for withholding versus perfect follow-up.

Conclusions Routine follow-up in ovarian cancer patients is not expected to improve the life expectancy. The timing of detection of recurrent ovarian cancer is immaterial until markedly improved treatment options become available.

  • Life expectancy
  • Markov model
  • Ovarian cancer
  • Routine follow-up

https://doi.org/10.1097/IGC.0b013e3182611451

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • This work was supported by a grant from the Dutch Cancer Society (grant no. KUN 2008-4086).

    • The authors declare no conflicts of interest.